These are the nominees in the category Young Researcher of the Year

The nomination process started in the fall of 2025, and the jury has received over 100 nominations for the 6 categories: Center of the Year, Researcher-Initiated Trial of the Year, Industry-Initiated Trial of the Year, Innovative Environment of the Year, Young Researcher of the Year, and Enthusiast of the Year.

After a thorough process, the jury has selected a few nominees in each of the 6 categories. From today and in the coming weeks, we will present these.

The nominees in the Young Researcher of the Year category are:

• Tine-Lise Kalleklev
• Peder Myhre
• Hamza Nahoui
• Jonas Pivoriunas

Tine-Lise Kalleklev

Tine-Lise Kalleklev is a physician at Oslo University Hospital, completed her LIS1 training and is in the process of specializing in medical biochemistry. She is a PhD candidate in a study at the Oslo Diabetes Research Centre that examines the effects of physical training on glucose metabolism in women with a history of gestational diabetes (the DIASA-Ex study). Kalleklev has been the central driving force in the daily execution of the study, which included 40 women. With a rare combination of structure, determination, and human closeness, she has handled everything from recruitment and coordination of examination days to logistics, sample collection, quality assurance, and data collection. With her enthusiasm and professional ambition, she represents a new generation of physicians who will redefine the research field in medical biochemistry and clinical metabolism.

Hamza Nahoui

Hamza Nahoui is a doctor at the Cardiology Department at Akershus University Hospital (Ahus) and has been crucial in getting NorTrials Cardiovascular up and running quickly. He has demonstrated impressive work capacity, taking on tasks both when asked and when he sees a need, contributing far beyond what can be expected. He has independently screened and included over 30 patients in an industry trial and has performed most of the echocardiographic examinations in the drug trials at Ahus. He has done this work without any allocated time for it in his actual position, and much has been done in his free time. He places great emphasis on ensuring that patients have the best possible experience. He has actively engaged in both industry trials, researcher-initiated trials, and in organizing professional evenings with industry and other hospitals. This has helped strengthen collaboration not only between industry and Ahus but also across hospitals.

Peder Myhre

Peder Myhre is a specialist in internal medicine and cardiology, the leader of NorTrials Cardiovascular, works as a senior physician at the Cardiology Department at Akershus University Hospital (Ahus), a senior physician at Rikshospitalet, Oslo University Hospital, and as a Professor I at the Institute of Clinical Medicine at the University of Oslo. He is an outstanding clinician and researcher, with a significant research career where several of his works have garnered international attention. The majority of Myhre's research has been in heart failure, and his research has contributed to improved diagnostic accuracy and risk stratification. Myhre has a broad international network with close collaborators among leaders in heart failure research worldwide. He has supervised 5 PhD candidates, one postdoc candidate, and 3 master's students, and has also been the main responsible for 8 researcher-initiated and 10 industry-initiated trials. Despite his young age, Myhre has managed to leave a deep mark in clinical practice, teaching, and research.

Jonas Pivoriunas

Jonas Pivoriunas is a physician at the Medical Department at Drammen Hospital and has a PhD degree in the research group for preventive cardiology (NORCOR). NORCOR significantly contributes to recruitment in clinical treatment studies at Drammen Hospital, and in this work, Pivoriunas is central. He establishes the trials and includes patients, putting in effort and work far beyond what is expected. Pivoriunas is the local project leader for three clinical treatment trials, two of which are newly established in 2025. He has done this alongside his own PhD on statins and preparations for his defense, which took place in December. He will also be the local project leader for two studies in the startup phase, one of which he is nationally responsible for. His work lays the foundation for the infrastructure for clinical treatment studies (KBS) in general and for the experience of study nurses. This better equips Drammen Hospital to continue including patients in clinical treatment studies in the future. This is especially relevant for a non-university hospital, where there has previously been limited infrastructure for research. NORCOR and Pivoriunas have changed this.